SLC5A2 and type 2 diabetes mellitus: A comparative study between metformin monotherapy and as a combination therapy (metformin + empagliflozin) in patients with T2DM and NAFLD showed superiority of the latter group for improvements in ALT and hepatic fibrosis, and therefore the degree of amelioration of SGLT2 inhibitor may be greater than that of metformin [32].